| DC60520 |
BMS-502（SCHEMBL21830991）
Featured
|
BMS-502 is a dual DGKα and ζ inhibitor. BMS-502 demonstrated dose-dependent immune stimulation in the mouse OT-1 model, setting the stage for a drug discovery program. |
|
| DC60521 |
pociredir
Featured
|
Pociredir is an embryonic ectoderm development (EED) protein inhibitor. Pociredir can be used for the research of inflammatory or hemoglobinopathies, such as sickle cell disease. |
|
| DC60522 |
TP0472993
Featured
|
TP0472993 is an oral 20-hydroxyeicosatetraenoic acid synthesis inhibitor
|
|
| DC60523 |
CT-3
Featured
|
CT-3 is an irreversible trypanosomal topo. II inhibitor. |
|
| DC60524 |
GNE-7883
Featured
|
GNE-7883 is a pan-TEAD inhibitor.
|
|
| DC60525 |
KCL-286
Featured
|
KCL-286 is an oral RARβ agonist. |
|
| DC60526 |
AEF 0117
Featured
|
AEF0117 is a Signaling-specific CB1 inhibitor.
|
|
| DC60527 |
LUNA18
Featured
|
LUNA18 is an 11-mer cyclic peptide inhibitor for the intracellular tough target RAS with Kd (KRAS/G12D) of 0.043 nM and cellular IC50 of 1.4 nM (AsPC-1). LUNA18 orally and dose-dependently exhibits potent anti-cancer activities in a mouse xenograft model. LUNA18 shows 21–47% oral bioavailability in animals such as mouse, rat, monkey, and dog and notably does not require special formulations.
|
|
| DC60528 |
DNL343
Featured
|
DNL343 is a potent, selective, and brain-penetrant eukaryotic translation initiation factor 2B (eIF2B) activator with ATF4 IC50 of 9.8 nM. |
|
| DC60529 |
LY3473329 (Muvalaplin)
Featured
|
LY3473329 (Muvalaplin) is a potent, multivalent disruptor of lipoprotein(a) (Lp(a)). LY3473329-HCl binds to apolipoprotein KIV8 selectively with a potency of 22 nM and inhibits the formation of Lp(a) particles in vitro with IC50 of 0.09 nM. |
|
| DC60530 |
BTK-IN-24(NX-5948)
Featured
|
NX-5948,be also known as BTK-IN-24,is an oral BTK degrader.
|
|
| DC60531 |
VX-548（Suzetrigine）
Featured
|
Suzetrigine is a SCN10A blocker. The SCN10A is associated with the onset of pain due to peripheral neuropathy. Suzetrigine functions as an analgesic.
|
|
| DC60532 |
BMS-986172
Featured
|
BMS-986172 is a highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a L BMS-986172 showed on-target- and mechanism-based pharmacology. Moreover, its favorable pharmacokinetic (PK) profile and the lack of species variability in the glucuronidation potential resulted in a greater confidence level in the projection of a low dose for achieving targeted efficacious exposures in humans. Consistent with these projections.
|
|
| DC60533 |
Encaleret
Featured
|
Encaleret, also known as JIT-305, is an oral calcium-sensing receptor (CaSR) antagonist, for the treatment of osteoporosis.
|
|
| DC60534 |
PF-07202954
Featured
|
PF-07202954 is a DGAT2 Inhibitor (IC50 = 10 nM) with Longer Predicted Half-Life.
|
|
| DC60535 |
NT-0796
Featured
|
NT-0796 is a Brain-Penetrant and Highly Potent. NLRP3 Inflammasome Inhibitor (IC50 = 0.32 nM) for Neuroinflammatory Disorders.
|
|
| DC65706 |
STM3006
Featured
|
STM3006 is a highly potent, selective and orally active METTL3 inhibitor. STM3006 can be used for the research of acute myeloid leukaemia (AML). |
|
| DC60536 |
Zosurabalpin (RG6006)
Featured
|
Zosurabalpin (RG6006) is a class of tethered macrocyclic peptide (MCP) antibiotic. Zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB (carbapenem-resistant acinetobacter baumannii) both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. |
|
| DC60538 |
TAK-994
Featured
|
TAK-994 is an oral, selective OX2R agonist developed by Takeda for the treatment of narcolepsy type 1 (with cataplexy) and type 2 (without cataplexy). The molecule follows Takeda’s previous clinical molecule, TAK-925 (danavorexton), which was the first OX2R agonist to be tested in people with NT1 but had poor oral bioavailability and was administered intravenously in the clinic. |
|
| DC60539 |
RAS Inhibitor A122
Featured
|
RAS Inhibitor A122 - This oral tri-complex RAS(MULTI)(ON) inhibitor is a relative from a patent application of the currently undisclosed RMC-6236, which is currently in Phase I/Ib clinical trials for solid tumors. The RAS(MULTI) series was identified via SBDD based on extensive knowledge of RAS tricomplex inhibitors such as G12C tricomplex inhibitor, RMC-6291. |
|
| DC60540 |
KIO-301
Featured
|
KIO-301 – A photoswitchable HCN channel blocker with positive initial results from a Phase I/II for retinitis pigmentosa and choroideremia study that is being developed by KIORA Therapeutics. |
|
| DC65707 |
Thiophene, 2-methyl-5-(phenylsulfonyl)-
Featured
|
|
|
| DC65708 |
3-Methyl-5-(methylsulfamoyl)thiophene-2-carboxylic acid
Featured
|
|
|
| DC65709 |
PS-13 precursor 19
Featured
|
PS-13 Precursor 19 is a critical intermediate in the synthesis of PS-13, a highly potent and selective COX-1 inhibitor. PS-13's exceptional selectivity for COX-1 over COX-2 makes it a promising compound for both therapeutic development and research applications focused on understanding COX-1-mediated processes. |
|
| DC65710 |
PS13
Featured
|
PS13 is a highly potent and selective COX-1 inhibitor, and its radiolabeled form, [¹¹C]PS13, is a promising PET radiotracer for imaging COX-1 expression in vivo. Its ability to selectively bind COX-1 in major organs, including the spleen, gastrointestinal tract, kidneys, and brain, makes it a valuable tool for studying COX-1-mediated processes in health and disease. This radiotracer has significant potential for advancing research and therapeutic development in COX-1-related conditions. |
|
| DC65711 |
SK-575
Featured
|
SK-575 is a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers. SK-575 potently inhibits the growth of cancer cells bearing BRCA1/2 mutations and induces potent and specific degradation of PARP1 in various human cancer cells even at low picomolar concentrations. SK-575 achieves durable tumor growth inhibition in mice when used as a single agent or in combination with cytotoxic agents, such as temozolomide and cisplatin. |
.jpg)
|
| DC60542 |
NP3-562
Featured
|
NP3-562 is a potent, orally bioavailable, tricyclic NLRP3 inhibitor with IC50 of 0.26 μM in the FP binding assay. NP3-562 demonstrates excellent potency in human whole blood and full inhibition of IL-1β release in a mouse acute peritonitis model. |
|
| DC65712 |
TL 13-27
Featured
|
TL 13-27 is a negative control for TL 12-186. Demonstrates no kinase degradation in vitro. |
|
| DC65713 |
mPEG-5000-DSPE, Na
Featured
|
DSPE-MPEG(5000) is a PEGylated form of 1,2-distearoyl-rac-glycero-3-PE (DSPE). It has been used in the synthesis of lipid nanoparticles (LNPs) and liposomes for in vitro and in vivo two-photon bioimaging. |
|
| DC90033 |
RGT1383
Featured
|
RGT1383 is a novel GLP-1R agonist, an analog of PF-06882961. |
|
